Inhibrx (NASDAQ:INBX – Get Free Report) and Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.
Earnings & Valuation
This table compares Inhibrx and Kyverna Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibrx | $1.57 million | 134.79 | -$154.96 million | N/A | N/A |
| Kyverna Therapeutics | $7.03 million | 24.56 | -$60.37 million | N/A | N/A |
Kyverna Therapeutics has higher revenue and earnings than Inhibrx.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibrx | 0 | 2 | 0 | 0 | 2.00 |
| Kyverna Therapeutics | 0 | 1 | 7 | 1 | 3.00 |
Kyverna Therapeutics has a consensus price target of $25.71, indicating a potential upside of 542.86%. Given Kyverna Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Inhibrx.
Institutional & Insider Ownership
82.5% of Inhibrx shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 22.2% of Inhibrx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Inhibrx and Kyverna Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibrx | N/A | -113.74% | -80.56% |
| Kyverna Therapeutics | N/A | -51.12% | -37.91% |
Summary
Kyverna Therapeutics beats Inhibrx on 8 of the 11 factors compared between the two stocks.
About Inhibrx
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
